Meta-analysis for the association between overall survival and progression-free survival in gastrointestinal stromal tumor

Clinical Cancer Research

Volumn 21, Issue 2, 2015, Pages 295-302

  Özer Stillman, Ipek ^a   Strand, Lauren ^a   Chang, Jane ^b   Mohamed, Ateesha F ^b   Tranbarger Freier, Katherine E ^a  

^a EVIDERA   (United States)

^b Bayer HealthCare Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; DOVITINIB; DOXORUBICIN; EVEROLIMUS; IMATINIB; MOTESANIB; NILOTINIB; REGORAFENIB; SORAFENIB; SUNITINIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ARTICLE; BEST SUPPORTIVE CARE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LINEAR REGRESSION ANALYSIS; META ANALYSIS; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT CARE; PROGRESSION FREE SURVIVAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; VALIDATION PROCESS; DISEASE FREE SURVIVAL; GASTROINTESTINAL STROMAL TUMORS; GASTROINTESTINAL TUMOR; MORTALITY;

ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS;

EID: 84920945950     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1779     Document Type: Article

References (41)

1. Judson I, Demetri G. Advances in the treatment of gastrointestinal stromal tumors. Ann Oncol 2007;18 Suppl 10:x20-x24.
2. Reddy P, Boci K, Charbonneau C. The epidemiologic, health-related quality of life, and economic burden of gastrointestinal stromal tumors. J Clin Pharm Ther 2007;32:557-65.
3. Chiang NJ, Chen LT, Tsai CR, Chang JS. The epidemiology of gastrointestinal stromal tumors in Taiwan, 1998-2008: A nation-wide cancer registry based study. BMC Cancer 2014;14:102.
4. Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: An analysis of 1, 458 cases from 1992 to 2000.Am J Gastroenterol 2005;100:162-8.
5. Blanke CD, Rankin C, Demetri GD, Ryan CW, Von Mehren M, Benjamin RS, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008;26:626-32.
6. George S, Blay JY, Casali PG, Le Cesne A, Stephenson P, DePrimo SE, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumor after imatinib failure. Eur J Cancer 2009;45:1959-68.
7. George S, Feng Y, Von Mehren M, Choy E, Corless CL, Hornick JL, et al. Prolonged survival and disease control in the academic phase II trial of regorafenib in GIST: Response based on genotype. J Clin Oncol 31, 2013 (suppl; abstr 10511).
8. Park SH, Ryu MH, Ryoo BY, Im SA, Kwon HC, Lee SS, et al. Sora fenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: A phase II study of Korean gastrointestinal stromal tumors study group. Invest New Drugs 2012;30:2377-83.
9. Schoffski P, Reichardt P, Blay JY, DumezH, Morgan JA, Ray-Coquard I, et al. A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Ann Oncol 2010;21:1990-8.
10. Trent JC, Wathen K, Von Mehren M, Samuels BL, Staddon AP, Choy E, et al. A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol 29: 2011 (suppl; abstr 10006).
11. Artinyan A, Kim J, Soriano P, Chow W, Bhatia S, Ellenhorn JD. Metastatic gastrointestinal stromal tumors in the era of imatinib: Improved survival and elimination of socioeconomic survival disparities. Cancer Epidemiol Biomarkers Prev 2008;17:2194-201.
12. Casali PG. Successes and limitations of targeted cancer therapy in gastrointestinal stromal tumors. Prog Tumor Res 2014;41:51-61.
13. Buyse M. Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials. Cancer J 2009;15:421-5.
14. Petrelli F, Barni S. Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer. Ann Oncol 2013;24:186-92.
15. Sidhu R, Rong A, Dahlberg S. Evaluation of progression-free survival as a surrogate endpoint for survival in chemotherapy and targeted agent metastatic colorectal cancer trials. Clin Cancer Res 2013;19:969-76.
16. Buyse M, Burzykowski T, Carroll K, Michiels S, Sargent DJ, Miller LL, et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 2007;25:5218-24.
17. Mayfield E. Progression-free survival: patient benefit or lower standard? NCI Cancer Bulletin 2008;5:1-11.
18. Joensuu H. Current perspectives on the epidemiology of gastrointestinal stromal tumors. EJC Supplements 2006;4:44-9.
19. Pazdur R. Endpoints for assessing drug activity in clinical trials. Oncologist 2008;13:19-21.
20. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 The Cochrane Collaboration; 2011. [Accessed September 4, 2014]. Available from: www.cochrane-handbook.org.
21. OkenMM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
22. Neter J, Kutner M, Nachtsheim C, Wasserman W. Applied linear statistical models. 4th ed. New York: McGraw-Hill/Irwin; 1996.
23. Benjamin RS, Schoffski P, Hartmann JT, Van Oosterom A, Bui BN, Duyster J, et al. Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors. Cancer Chemother Pharmacol 2011;68:69-77.
24. Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CDM, et al. Correlation of kinase genotype and clinical outcome in the North American intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by cancer and leukemia group B and southwest oncology group. J Clin Oncol 2008;26:5360-7.
25. Italiano A, Cioffi A, Coco P, Maki RG, Schoffski P, Rutkowski P, et al. Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib. Ann Surg Oncol 2012;19:1551-9.
26. Kang Y, Ryu M, Lee J, Park JH, Ryoo B. A phase II study of dovitinib in patients with metastatic or unresectable gastrointestinal stromal tumors after failure of two or more tyrosine kinase inhibitors. Poster Discussion at European Society of Medical Oncology (ESMO) 37th Congress, Vienna. Ann. Oncol. 2012;23(Suppl 9):Abstract 1481PD, Page ix1480.
27. Kang YK, Ryu MH, Yoo C, Ryoo BY, Kim HJ, Lee JJ, et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): A randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2013;14:1175-82.
28. Kindler HL, Campbell NP, Wroblewski K, Maki RG, D'Adamo DR, Cho WA, et al. Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): final results of a University of Chicago Phase II Consortium trial. JClin Oncol 2011;suppl; abstr 10009.
29. Li J, Gong JF, Li J, Gao J, Sun NP, Shen L. Efficacy of imatinib dose escalation in Chinese gastrointestinal stromal tumor patients. World J Gastroenterol 2012;18:698-703.
30. Maurel J, Martins AS, Poveda A, Lopez-Guerrero JA, Cubedo R, Casado A, et al. Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: A phase I-II study by the Spanish Group for Research on Sarcomas. Cancer 2010;116:3692-701.
31. McAuliffe JC, Hunt KK, Lazar AJF, Choi H, Qiao W, Thall P, et al. A randomized, phase II study of preoperative plus postoperative Imatinib in GIST: Evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol 2009;16:910-9.
32. Montemurro M, Gelderblom H, Bitz U, Schutte J, Blay JY, Joensuu H, et al. Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumor and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis. Eur J Cancer 2013;49:1027-31.
33. Raut CP, Wang Q, Manola J, Morgan JA, George S, Wagner AJ, et al. Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate. Ann Surg Oncol 2010;17:407-15.
34. Reichardt P, Blay JY, Gelderblom H, Schlemmer M, Demetri GD, Bui- Nguyen B, et al. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Ann Oncol 2012;23:1680-7.
35. Ryu MH, Kang WK, Bang YJ, Lee KH, Shin DB, Ryoo BY, et al. A prospective, multicenter, phase 2 study of imatinib mesylate in Korean patients with metastatic or unresectable gastrointestinal stromal tumor. Oncology 2009;76:326-32.
36. McAuliffe JC, Lazar AJF, Yang D, Steinert DM, Qiao W, Thall PF, et al. Association of intra tumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate. Clin Cancer Res 2007;13:6727-34.
37. Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009;101:1642-9.
38. Chirila C, Odom D, Devercelli G, Khan S, Sherif BN, Kaye JA, et al. Meta analysis of the association between progression-free survival and overall survival in metastatic colorectal cancer. Int J Colorectal Dis 2012;27: 623-34.
39. Petrelli F, Barni S. Surrogate endpoints in metastatic breast cancer treated with targeted therapies: An analysis of the first-line phase III trials. Med Oncol 2014;31:776.
40. Beauchemin C, Johnston J, Lapierre ME, Aissa F, Lachaine J. Relationship between progression-free survival and overall survival in chronic lymphocytic leukemia. Value Health 2012;15:A414-5.
41. Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 2000;1:49-67.